All questions
Safety: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults 5 questions · 3 sources
Safety questions that apply to every indication of Prevnar 20 are on Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), all indications: Safety .
Side effects What are the most common side effects of Prevnar 20 in adults? Prevnar 20 vs Prevnar 13: how common were side effects in Study 1? “Study 1 was conducted in the U.S. and in Sweden.
Local reactions measured within 10 days after vaccination; systemic reactions measured within 7 days after vaccination.
n=number of participants with any e-diary data reported after vaccination (after Vaccination 1 [Prevnar 20 or PCV13] for Study 1 participants age 60 or older). This value is the denominator for the percentage calculations.
Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 10 after vaccination.
Diameters were measured in caliper units (0.5 cm) of whole numbers from 1 to 21 or 21+. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling was characterized as: mild is >2.0 to 5.0 cm; moderate is >5.0 to 10.0 cm; severe is >10.0 cm.
“Any local reaction” includes all participants who reported any injection site reaction (pain, swelling, or redness) as mild, moderate, or severe during Day 1 to Day 10 after vaccination.
Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 7 after vaccination.
“Any systemic reaction” includes all participants who reported any fever ≥38 °C or any other systemic reaction (fatigue, headache, joint pain, or muscle pain) as mild, moderate, or severe during Day 1 to Day 7 after vaccination.
Severity was not collected for use of antipyretic or pain medication. The numbers listed reflect “yes” responses (ie, number of reactions reported).” (opens the source at this quote in a new tab) Copy Flag
Note: The column headings Prevnar 20/Saline and PCV13/PPSV23 refer to the Study 1 design for participants 60 years and older, who received Prevnar 20 followed 1 month later by saline placebo or Prevnar 13 followed 1 month later by PPSV23 (Prescribing Information, section 14.3).
How common are Prevnar 20 side effects in previously vaccinated adults 65+? Applies to Adults 65 years of age and older previously vaccinated with a pneumococcal vaccine (Study 6)
“Study 6 was conducted in the U.S. and in Sweden.
Open-label administration of Prevnar 20.
Includes participants who previously received either PPSV23 ≥1 to ≤5 years before enrollment, PCV13 ≥6 months before enrollment, or PCV13 followed by PPSV23 ≥1 year before enrollment in the study.
Local reactions measured within 10 days after vaccination; systemic reactions measured within 7 days after vaccination.
n=number of participants with any e-diary data reported after vaccination. This value is the denominator for the percentage calculations.
Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 10 after vaccination.
Diameters were measured in caliper units (0.5 cm) of whole numbers from 1 to 21 or 21+. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling was characterized as: mild is >2.0 to 5.0 cm; moderate is >5.0 to 10.0 cm; severe is >10.0 cm.
“Any local reaction” includes all participants who reported any injection site reaction (pain, swelling, or redness) as mild, moderate, or severe during Day 1 to Day 10 after vaccination.
Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 7 after vaccination.
”Any systemic reaction” includes all participants who reported any fever ≥38 °C or any other systemic reaction (fatigue, headache, joint pain, or muscle pain) as mild, moderate, or severe during Day 1 to Day 7 after vaccination.
Severity was not collected for use of antipyretic or pain medication. The numbers listed reflect “yes” responses (ie, number of reactions reported).” (opens the source at this quote in a new tab) Copy Flag
How common were serious adverse events with Prevnar 20 in adult trials? Which Prevnar 13 postmarketing side effects may also occur with Prevnar 20? Applies to Prevnar 13 postmarketing reports that the label states may also be seen with Prevnar 20
Note: The label's list also names reactions reported in pediatric populations only (cyanosis, hypotonia, apnea, pallor), which are omitted here.